CD8A and neoplasm: Anti‐PD‐1 antibody treatment increased tumor T‐cell numbers and activation in this setting, likely by activating the 40% of tumor CD4+ T cells and 70% of tumor CD8+ T cells expressing PD‐1, a marker of T‐cell exhaustion.